TY - JOUR
T1 - Mesenchymal Stem Cells in Fibrotic Disease
AU - El Agha, Elie
AU - Kramann, Rafael
AU - Schneider, Rebekka K.
AU - Li, Xiaokun
AU - Seeger, Werner
AU - Humphreys, Benjamin D.
AU - Bellusci, Saverio
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/8/3
Y1 - 2017/8/3
N2 - Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation. Investigating the cellular origin of myofibroblasts in various diseases is thus a promising strategy for developing targeted anti-fibrotic treatments. Recent studies using genetic lineage tracing technology have implicated diverse organ-resident perivascular mesenchymal stem cell (MSC)-like cells and bone marrow-MSCs in myofibroblast generation during fibrosis development. In this Review, we give an overview of the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow. Fibrosis is associated with organ failure and is characterized by aberrant myofibroblast accumulation; thus, investigating the cellular origin of myofibroblasts is a promising therapeutic strategy. Here we discuss the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.
AB - Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation. Investigating the cellular origin of myofibroblasts in various diseases is thus a promising strategy for developing targeted anti-fibrotic treatments. Recent studies using genetic lineage tracing technology have implicated diverse organ-resident perivascular mesenchymal stem cell (MSC)-like cells and bone marrow-MSCs in myofibroblast generation during fibrosis development. In this Review, we give an overview of the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow. Fibrosis is associated with organ failure and is characterized by aberrant myofibroblast accumulation; thus, investigating the cellular origin of myofibroblasts is a promising therapeutic strategy. Here we discuss the emerging role of MSCs and MSC-like cells in myofibroblast-mediated fibrotic disease in the kidney, lung, heart, liver, skin, and bone marrow.
KW - lineage tracing
KW - mesenchymal stem cells
KW - organ fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85030481526&partnerID=8YFLogxK
U2 - 10.1016/j.stem.2017.07.011
DO - 10.1016/j.stem.2017.07.011
M3 - Review article
C2 - 28777943
AN - SCOPUS:85030481526
SN - 1934-5909
VL - 21
SP - 166
EP - 177
JO - Cell Stem Cell
JF - Cell Stem Cell
IS - 2
ER -